Oxford Properties Invests In UK Life Sciences Sector
Date posted:
News
Global real estate investor Oxford Properties has completed its investment in the life sciences sector in Europe by acquiring 310 Cambridge Science Park. Cambridge Network reported that the organisation has been focusing on building a “substantial and dedicated life sciences business” since 2017.
This acquisition in the UK is the organisation’s seventh in the life sciences space since the beginning of 2021.
However, this is just the beginning of Oxford’s investment in the life sciences sector in Europe. The company revealed it intends to deploy some £1.2 billion of investment in European life sciences assets in the coming five years.
It already holds a life science portfolio in North America that is worth $1.1 billion. It intends to focus on building its life science property portfolio in Europe using various entry points to the market, including investments in platforms, direct property acquisitions and developments, and via debt.
An article for Building Design recently noted that developer British Land and consultant Alinea are targeting the life sciences sector this year as well.
British Land is reportedly looking to diversify its portfolio following the pandemic, which has seen it take a hit. As a result, it is targeting tenants in the life sciences sector, as well as exploring opportunities in the logistics market.
Founding partner at Alinea Mark Lacey told the publication that he believes the life sciences sector will be “massive” for London. “King’s Cross is a bit of a bullseye for life sciences because of the Francis Crick Institute, the Wellcome Trust and the universities around there,” he explained.
Looking for assistance with lead generation in life sciences? Get in touch with our team today.